SCHEMBL588023

SCHEMBL588023

COC(=O)C1CCN(C(=O)OC)C(Cc2ccc(F)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 1/20 0.45
MMP1 P03956 2/20 0.44
ADAM17 P78536 2/20 0.44
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SLC6A2 P23975 3/20 0.39
SLC6A4 P31645 3/20 0.39
CCR3 P51677 3/20 0.39
SLC6A3 Q01959 3/20 0.39
KMT2A Q03164 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL580834 0.91 NOTUM (0.41) ALDH1A1SMN1; SMN2HTTMAPTSLC6A2
SCHEMBL586739 0.88 OPRK1 (0.50) OPRK1ALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL587405 0.88 OPRK1 (0.43) OPRK1MMP1ADAM17ALDH1A1SMN1; SMN2
SCHEMBL587316 0.87 ALDH1A1 (0.47) OPRK1MMP1ADAM17ALDH1A1SMN1; SMN2
SCHEMBL586823 0.87 TACR1 (0.44) OPRK1ALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL586767 0.86 ALDH1A1 (0.43) OPRK1ALDH1A1MAPTHPGDNPSR1
SCHEMBL587859 0.85 POLB (0.44) OPRK1ALDH1A1KMT2ACYP3A4CYP2D6
SCHEMBL586837 0.85 ALDH1A1 (0.44) OPRK1MMP1ADAM17ALDH1A1SMN1; SMN2
SCHEMBL586719 0.85 OPRK1 (0.42) OPRK1MMP1ADAM17ALDH1A1SMN1; SMN2
SCHEMBL586861 0.84 ALDH1A1 (0.47) OPRK1MMP1ADAM17ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 OPRK1 164/4885MMP1 3879/4885ADAM17 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.